Bluebird bio Inc., a Cambridge gene therapy company that had an initial public stock offering in June, said Monday the first patient has undergone infusion with its Lenti-D drug product in a stem cell transplantation.
The company, which looks to develop next generation products to treat patients with severe genetic and orphan diseases, has been working on a therapy to slow the progression of a genetic brain disorder called childhood cerebral adrenoleukodystrophy, or CCALD.
In a Monday press release, bluebird bio said that the first subject in its phase 2/3 study had undergone infusion with the drug in an autologous hematopoietic stem cell transplantation.
Bluebird bio is one of more than half a dozen Massachusetts biotech companies that have gone public so far this year, including Enanta Pharmaceuticals Inc. and Tetraphase Pharmaceuticals Inc. of Watertown and Cambridge-based Epizyme Inc., Agios Pharmaceuticals Inc., and Acceleron Pharma Inc.
Chris Reidy can be reached at firstname.lastname@example.org.